MIRA PHARMACEUTICALS, INC. (MIRA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | - | - | - | - |
| Other income/(expense) | -107 | - | - | - |
| Research and development expenses | 496,197 | 314,404 | 1,067,396 | 614,462 |
| General and administrative expenses | 1,049,903 | 1,490,796 | 1,014,223 | 1,116,260 |
| Total operating costs | 1,546,100 | 1,805,200 | 2,081,619 | 1,730,722 |
| Interest income | 8,495 | - | - | - |
| Interest income | - | -21,421 | -37,752 | -39,397 |
| Net loss | -1,537,712 | -1,783,779 | -2,043,867 | -1,691,325 |
| Basic loss per share | -0.09 | -0.11 | -0.14 | -0.11 |
| Diluted loss per share | -0.09 | -0.11 | -0.14 | -0.11 |
| Weighted average common stock shares outstanding - basic | 16,986,488 | 16,645,119 | 15,071,915 | 14,780,885 |
| Weighted average common stock shares outstanding - diluted | 16,986,488 | 16,645,119 | 15,071,915 | 14,780,885 |